Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 9/20 | 0.46 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537943 | 0.83 | NOTUM (0.33) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL144068 | 0.82 | NOTUM (0.37) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2046047 | 0.78 | NOTUM (0.37) | NOTUM | |
| SCHEMBL15263626 | 0.78 | STK17B (0.37) | IDO1 | |
| SCHEMBL7413160 | 0.77 | SMN1; SMN2 (0.32) | LMNA | |
| SCHEMBL2698021 | 0.76 | NOTUM (0.61) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL987352 | 0.76 | IDO1 (0.50) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29649700 | 0.76 | IDO1 (0.50) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| Bromide SCHEMBL9619767 | 0.76 | IDO1 (0.46) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1040760 | 0.74 | CES2 (0.50) | IDO1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113754569-B | Intermediate compound and preparation method and application thereof | 四川国为制药有限公司 | 2024-07-02 | — | — | CN | claimed |
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| CN-112694473-A | 7, 9-disubstituted berberine derivative and preparation method and application thereof | 南京林业大学 | 2021-04-23 | — | — | CN | claimed |
| CN-109678872-B | Bisbenzylisoquinoline compound and preparation method and application thereof | 山东师范大学 | 2020-09-29 | — | — | CN | claimed |
| CN-110577563-B | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2020-09-04 | — | — | CN | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | ABBVIE INC. (US) | 2020-02-11 | — | — | US | claimed |
| CN-110577563-A | Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs | 山东师范大学 | 2019-12-17 | — | — | CN | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| EP-3350187-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | claimed |
| EP-1351688-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| US-6495540-B2 | HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR | BRISTOL - MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | claimed |
| WO-2002047687-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | claimed |
| US-6407100-B1 | HORTICULTURE, AGRICULTURE, WOOD PRESERVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-18 | — | — | US | claimed |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-24 | — | — | US | claimed |
| EP-0835242-A1 | THIOAMIDES S-OXIDES FOR USE AS PESTICIDES | Novartis AG (CH) | 1998-04-15 | — | — | EP | claimed |
| EP-0777645-A1 | OXIME ETHERS AND THEIR USE AS PESTICIDES | Novartis AG (CH) | 1997-06-11 | — | — | EP | claimed |
| WO-1997000859-A1 | THIOAMIDES S-OXIDES FOR USE AS PESTICIDES | NOVARTIS AG (CH) | 1997-01-09 | — | — | WO | claimed |
| WO-1996006072-A1 | OXIME ETHERS AND THEIR USE AS PESTICIDES | CIBA-GEIGY AG (CH) | 1996-02-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556914-B2 | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use | GABRB1, GABBR1, GABBR2 | IDO1 1378/4885HTR3E 571/4885HTR3B 182/4885 |
| US-20040039017-A1 | Urotensin-II receptor antagonists | UTS2R, NTSR2, PLAUR | IDO1 1383/4885HTR3E 257/4885HTR3B 224/4885 |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BACE1, APP, APH1A | IDO1 2498/4885HTR3E 4683/4885HTR3B 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.